Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CareDx, Inc. (Nasdaq: CDNA) announced its participation at the 36th European Immunogenetics and Histocompatibility Conference from April 26-29 in Nantes, France. The company will showcase its AlloSeq portfolio for HLA typing and organ transplant monitoring, highlighting innovations in precision medicine for transplant patients.
The event will feature a symposium focused on innovative pre- and post-transplant solutions, moderated by Curtis Lind, with discussions led by various experts on HLA typing and chimerism analysis. CareDx emphasizes its commitment to advancing immunogenetics and supporting the European transplant community.
The AlloSeq products aim to enhance pre- and post-transplant care, reinforcing CareDx’s leadership in the transplant genomics market.
CareDx, Inc. (CDNA) announces its significant participation in the 43rd annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in Denver, Colorado, showcasing over 55 presentations on advancements in heart and lung transplantation. The presentation highlights the clinical benefits of HeartCare and AlloSure Lung, focusing on their utility in post-transplant care. Experts, including Dr. Jeffrey Teuteberg from Stanford, advocate for moving away from biopsies to molecular surveillance for better outcomes. The event takes place from April 19-22, underscoring CareDx's commitment to enhancing clinical decision-making with its non-invasive solutions. CEO Reg Seeto emphasizes that the research will provide insights into patient care.
Summary not available.